Takeda Announces Establishment of Development Center in China

Takeda Announces Establishment of Development Center in China

February 9, 2012
Takeda Pharmaceutical Company Limited Takeda Announces Establishment of Development Center in China

Osaka, Japan, February 09, 2012-Takeda Pharmaceutical Company Limited ("Takeda") announced today the establishment of the Takeda Shanghai Development Center ("TSDC") within the Shanghai-based Takeda (China) Holdings Co., Ltd. ("TCH"), which is a wholly owned subsidiary of Takeda.

This important step reflects Takeda's strategic commitment to Asia and to China in particular. Takeda is now enhancing its business in China through TCH's wholly owned subsidiaries, Takeda Pharmaceutical (China) Company Limited in Taizhou ("Takeda China"), which is responsible for manufacturing, and Tianjin Takeda Pharmaceuticals Co., Ltd, in Tianjin ("Tianjin Takeda"), which is responsible for marketing and sales. Together with Takeda China and Tianjin Takeda, TSDC will help to drive Takeda's ambitious growth agenda in China and in the broader Asian region.

Within Asia outside Japan, including China, drug development is overseen by Takeda Global Research & Development Center (Asia) Pte. Ltd. in Singapore ("TGRD (Asia)") and Millennium Pharmaceuticals Inc. in Cambridge ("Millennium"), wholly owned subsidiaries of Takeda, through outsourcing to contract research organizations. The establishment of TSDC will provide a powerful addition to this global development infrastructure. TSDC will work on extending and enhancing the company's clinical development activities within the Asian region, with a focus on China for General Medicine working as an integrated regional team with TGRD (Asia), and across Asia for Oncology. The team will be composed of personnel from both the Pharmaceutical Development Division and Millennium, and will draw on the rich pool of talent and expertise in China. Through the resources of TSDC, Takeda will continue to conduct high quality clinical trials which will lead to secure regulatory approval in Asia, with a growing emphasis on China, and continue to build deeper relationships with physicians and regulatory authorities.


Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.